These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9550623)

  • 41. Relation of lipid abnormalities to progression of renal damage in essential hypertension, insulin-dependent and non insulin-dependent diabetes mellitus.
    Walker WG
    Miner Electrolyte Metab; 1993; 19(3):137-43. PubMed ID: 8232100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biology of proteoglycans in renal diseases.
    Kanwar YS
    Nihon Jinzo Gakkai Shi; 1992 May; 34(5):431-3. PubMed ID: 1469800
    [No Abstract]   [Full Text] [Related]  

  • 43. Has the proteome of formalin-fixed wax-embedded tissue been unlocked?
    Murray GI
    Nephrol Dial Transplant; 2012 Sep; 27(9):3395-8. PubMed ID: 22859788
    [No Abstract]   [Full Text] [Related]  

  • 44. Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy.
    Komers R; Anderson S
    Nephrol Dial Transplant; 2008 Sep; 23(9):3037; author reply 3037-8. PubMed ID: 18596128
    [No Abstract]   [Full Text] [Related]  

  • 45. Metabolomic biomarkers in diabetic kidney diseases--A systematic review.
    Zhang Y; Zhang S; Wang G
    J Diabetes Complications; 2015; 29(8):1345-51. PubMed ID: 26253264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The kidney and lipids: preface.
    Kasiske B; Saito T
    Clin Exp Nephrol; 2014 Apr; 18(2):180-4. PubMed ID: 24700157
    [No Abstract]   [Full Text] [Related]  

  • 47. [Glucose lowering drugs in case of impaired renal function].
    Assink MA; Abrahams AC; Rookmaaker MB
    Ned Tijdschr Geneeskd; 2014; 158():A6907. PubMed ID: 24618238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The significance of hypolipemic drugs in the inhibition of progression of renal failure].
    Chrzanowski W
    Pol Arch Med Wewn; 2002 Apr; 107(4):369-74. PubMed ID: 12189929
    [No Abstract]   [Full Text] [Related]  

  • 49. Diabetic nephropathy--a review.
    Acharya VN; Chawla KP
    J Postgrad Med; 1978 Jul; 24(3):138-46. PubMed ID: 364042
    [No Abstract]   [Full Text] [Related]  

  • 50. Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency.
    Verwoerd A; Vorselaars AD; van Moorsel CH; Bos WJ; van Velzen-Blad H; Grutters JC
    Eur Respir J; 2015 Jul; 46(1):277-80. PubMed ID: 25745051
    [No Abstract]   [Full Text] [Related]  

  • 51. Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy.
    Kolseth IB; Reine TM; Parker K; Sudworth A; Witczak BJ; Jenssen TG; Kolset SO
    J Diabetes Complications; 2017 Jan; 31(1):245-252. PubMed ID: 27452162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid-induced glomerular injury.
    Guijarro C; Keane WF
    Nephron; 1994; 67(1):1-6. PubMed ID: 8052348
    [No Abstract]   [Full Text] [Related]  

  • 53. Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis.
    Sakai T; Nambu T; Katoh M; Uehara S; Fukuroda T; Nishikibe M
    Biochem Biophys Res Commun; 2009 Jun; 384(2):173-9. PubMed ID: 19401193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth hormone expression is required for the development of diabetic glomerulosclerosis in mice.
    Liu ZH; Striker LJ; Phillips C; Chen NY; Chen WY; Kopchick JJ; Striker GE
    Kidney Int Suppl; 1995 Sep; 51():S37-8. PubMed ID: 7474687
    [No Abstract]   [Full Text] [Related]  

  • 55. Collagen turnover in renal disease.
    Costigan M; Chambers DA; Boot-Handford RP
    Exp Nephrol; 1995; 3(2):114-21. PubMed ID: 7773630
    [No Abstract]   [Full Text] [Related]  

  • 56. Role for GLUT1 in diabetic glomerulosclerosis.
    Heilig CW; Brosius FC; Cunningham C
    Expert Rev Mol Med; 2006 Feb; 8(4):1-18. PubMed ID: 16515729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperlipidemia and the progression of renal disease.
    Keane WF; Kasiske BL; O'Donnell MP
    Am J Clin Nutr; 1988 Jan; 47(1):157-60. PubMed ID: 3276133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy.
    Mise K; Hoshino J; Ueno T; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Fujii T; Hara S; Ohashi K; Takaichi K; Ubara Y
    Diabetes Res Clin Pract; 2014 Dec; 106(3):522-30. PubMed ID: 25458334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetic glomerulosclerosis: current status.
    Kalant N
    Can Med Assoc J; 1978 Jul; 119(2):146-53. PubMed ID: 354765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigation into the biochemical basis of diabetic basement-membrane alterations.
    Sprio RG
    Diabetes; 1976; 25(2 SUPPL):909-13. PubMed ID: 786762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.